Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Receivables (2020 - 2025)

Gain Therapeutics has reported Receivables over the past 5 years, most recently at $917094.0 for Q3 2025.

  • Quarterly results put Receivables at $917094.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $917094.0 (changed N/A YoY), and the annual figure for FY2024 was $494684.0, changed.
  • Receivables for Q3 2025 was $917094.0 at Gain Therapeutics, down from $1.5 million in the prior quarter.
  • Over the last five years, Receivables for GANX hit a ceiling of $1.5 million in Q2 2025 and a floor of $4486.0 in Q1 2021.
  • Median Receivables over the past 4 years was $353166.0 (2021), compared with a mean of $475626.8.
  • Biggest five-year swings in Receivables: skyrocketed 1815.35% in 2021 and later crashed 46.6% in 2022.
  • Gain Therapeutics' Receivables stood at $163724.0 in 2021, then tumbled by 46.6% to $87430.0 in 2022, then soared by 465.81% to $494684.0 in 2024, then surged by 85.39% to $917094.0 in 2025.
  • The last three reported values for Receivables were $917094.0 (Q3 2025), $1.5 million (Q2 2025), and $738961.0 (Q1 2025) per Business Quant data.